Ping An Healthcare 50 Select ETF (03500) rose more than 2%, up 2.44% as of press time to HK$16.39, with a turnover of HK$2.3055 million.

On the news front, on September 30, Ping An Healthcare 50 Select ETF (03500) officially listed on the Hong Kong Stock Exchange. The ETF tracks the Solactive G2 Healthcare 50 Select Income Index, focusing on 50 top listed healthcare enterprises in China and the United States: selecting Chinese "going global benchmarks" and American innovative drug leaders, balancing growth potential and global competitiveness.

Examples include Merck & Co, Johnson & Johnson, Eli Lilly, WuXi AppTec, Innovent Biologics, and others.

It is worth noting that the pharmaceutical industry has recently seen a continuous stream of positive developments. On the policy side, the U.S. Treasury Department's new rules on investment in China are expected to preserve the ability of American pharmaceutical companies to reach licensing agreements with Chinese drugmakers; during the same period, China's domestic pharmaceutical industry "15th Five-Year Plan" was released, further strengthening the positioning of biopharmaceuticals as an emerging pillar industry.

On the industry side, AI4S in the pharmaceutical field is entering a stage of cross-sector giant competition, with the focus of competition extending from model capabilities to the closed-loop efficiency of computational design and experimental validation.